177 related articles for article (PubMed ID: 37962616)
21. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
22. PET/CT imaging in neuroblastoma.
Piccardo A; Lopci E; Conte M; Foppiani L; Garaventa A; Cabria M; Villavecchia G; Fanti S; Cistaro A
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):29-39. PubMed ID: 23474633
[TBL] [Abstract][Full Text] [Related]
23. Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments.
Samim A; Tytgat GAM; Bleeker G; Wenker STM; Chatalic KLS; Poot AJ; Tolboom N; van Noesel MM; Lam MGEH; de Keizer B
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33916640
[TBL] [Abstract][Full Text] [Related]
24. Head-to-head comparison between
Piccardo A; Fiz F; Bottoni G; Ugolini M; Noordzij W; Trimboli P
Clin Endocrinol (Oxf); 2021 Oct; 95(4):595-605. PubMed ID: 34018606
[TBL] [Abstract][Full Text] [Related]
25. Biodistribution and Dosimetry of
Pandit-Taskar N; Zanzonico P; Staton KD; Carrasquillo JA; Reidy-Lagunes D; Lyashchenko S; Burnazi E; Zhang H; Lewis JS; Blasberg R; Larson SM; Weber WA; Modak S
J Nucl Med; 2018 Jan; 59(1):147-153. PubMed ID: 28705916
[No Abstract] [Full Text] [Related]
26. Compared to
Kroiss AS; Uprimny C; Shulkin BL; Frech A; Tilg H; Gasser RW; Sprinzl GM; Gruber L; Thomé C; Plangger C; Url C; Fraedrich G; Virgolini IJ
Ann Nucl Med; 2017 Jun; 31(5):357-365. PubMed ID: 28349331
[TBL] [Abstract][Full Text] [Related]
27. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
[TBL] [Abstract][Full Text] [Related]
28. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
[TBL] [Abstract][Full Text] [Related]
29. ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.
Melzer HI; Coppenrath E; Schmid I; Albert MH; von Schweinitz D; Tudball C; Bartenstein P; Pfluger T
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1648-58. PubMed ID: 21617976
[TBL] [Abstract][Full Text] [Related]
30. Prone-position acquisition of myocardial (123)I-metaiodobenzylguanidine (MIBG) SPECT reveals regional uptake similar to that found using (11)C-hydroxyephedrine PET/CT.
Yoshinaga K; Tomiyama Y; Manabe O; Kasai K; Katoh C; Magota K; Suzuki E; Nishijima K; Kuge Y; Ito YM; Tamaki N
Ann Nucl Med; 2014 Oct; 28(8):761-9. PubMed ID: 24950751
[TBL] [Abstract][Full Text] [Related]
31.
Aboian MS; Huang SY; Hernandez-Pampaloni M; Hawkins RA; VanBrocklin HF; Huh Y; Vo KT; Gustafson WC; Matthay KK; Seo Y
J Nucl Med; 2021 Jan; 62(1):43-47. PubMed ID: 32414950
[TBL] [Abstract][Full Text] [Related]
32. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
34. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
35. Iodine-123 metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular dysfunction.
Matsunari I; Aoki H; Nomura Y; Takeda N; Chen WP; Taki J; Nakajima K; Nekolla SG; Kinuya S; Kajinami K
Circ Cardiovasc Imaging; 2010 Sep; 3(5):595-603. PubMed ID: 20534790
[TBL] [Abstract][Full Text] [Related]
36. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy.
Boubaker A; Bischof Delaloye A
Q J Nucl Med; 2003 Mar; 47(1):31-40. PubMed ID: 12714952
[TBL] [Abstract][Full Text] [Related]
37. Bone and lymph node metastases from neuroblastoma detected by 18F-DOPA-PET/CT and confirmed by posttherapy 131I-MIBG but negative on diagnostic 123I-MIBG scan.
Piccardo A; Lopci E; Conte M; Cabria M; Cistaro A; Garaventa A; Villavecchia G
Clin Nucl Med; 2014 Jan; 39(1):e80-3. PubMed ID: 23579975
[TBL] [Abstract][Full Text] [Related]
38. PET hydroxyephedrine imaging of neuroblastoma.
Shulkin BL; Wieland DM; Baro ME; Ungar DR; Mitchell DS; Dole MG; Rawwas JB; Castle VP; Sisson JC; Hutchinson RJ
J Nucl Med; 1996 Jan; 37(1):16-21. PubMed ID: 8543986
[TBL] [Abstract][Full Text] [Related]
39. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
Taggart DR; Han MM; Quach A; Groshen S; Ye W; Villablanca JG; Jackson HA; Mari Aparici C; Carlson D; Maris J; Hawkins R; Matthay KK
J Clin Oncol; 2009 Nov; 27(32):5343-9. PubMed ID: 19805691
[TBL] [Abstract][Full Text] [Related]
40. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
